[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587426":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":11,"studyPopulation":11,"armGroups":34,"interventions":44,"overallOfficials":50,"centralContacts":54,"locations":59,"responsibleParty":78,"collaborators":11,"id":81,"slug":11,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":11,"enrollmentInfo":91,"targetDuration":11,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":61,"whyStopped":11,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Allele frequency of TNFAIP3 variants in cases vs controls",null,"Baseline",[14,17,19,22,25],{"measure":15,"description":16,"timeFrame":12},"TNFAIP3 (A20) mRNA expression levels in peripheral blood","TNFAIP3 (A20) mRNA expression levels in peripheral blood of cases versus controls",{"measure":18,"description":11,"timeFrame":12},"Association between TNFAIP3 genotype and gene expression",{"measure":20,"description":21,"timeFrame":12},"Clinical relapse rate of iTTP during follow-up","Association between TNFAIP3\u002FA20 variation and iTTP relapse in iTTP patients",{"measure":23,"description":24,"timeFrame":12},"Severity of acute iTTP episodes","Association between TNFAIP3\u002FA20 variation and the severity of acute iTTP (composite endpoint including death, treatment refractoriness, exacerbation, and prolonged disease course)",{"measure":26,"description":27,"timeFrame":12},"Age at iTTP onset","Association between TNFAIP3\u002FA20 variation and age at onset in iTTP patients",{"allocation":29,"interventionModel":30,"interventionModelDescription":11,"primaryPurpose":31,"observationalModel":11,"timePerspective":11,"maskingInfo":32},"NON_RANDOMIZED","PARALLEL","BASIC_SCIENCE",{"masking":33,"maskingDescription":11,"whoMasked":11},"NONE",[35,40],{"label":36,"type":6,"description":37,"interventionNames":38},"Patients with iTTP","Intervention: blood sampling during standard collection for routine testing, with additional sample for experimental analyses.",[39],"Procedure: blood sampling",{"label":41,"type":6,"description":42,"interventionNames":43},"Healthy donors","Intervention: blood sampling during standard donation, with an additional sample collected for experimental analyses.",[39],[45],{"type":46,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"PROCEDURE","blood sampling","Blood sampling for experimental analyses.",[41,36],[51],{"name":52,"affiliation":5,"role":53},"Ilaria Mancini, PhD","PRINCIPAL_INVESTIGATOR",[55],{"name":52,"role":56,"phone":57,"phoneExt":11,"email":58},"CONTACT","+390255035414","ilaria.mancini@guest.unimi.it",[60],{"facility":5,"status":61,"city":62,"state":11,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"RECRUITING","Milan","20122","Italy","IT",{"type":67,"coordinates":68},"Point",[69,70],9.18951,45.46427,{"lat":70,"lon":69},[73,74,75],{"name":52,"role":56,"phone":57,"phoneExt":11,"email":58},{"name":52,"role":53,"phone":11,"phoneExt":11,"email":11},{"name":76,"role":77,"phone":11,"phoneExt":11,"email":11},"Andrea Artoni, MD, PhD","SUB_INVESTIGATOR",{"type":53,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Ilaria Mancini","PhD","100587426",false,"NCT06928233","Association of TNFAIP3 With Immune-mediated TTP","Association of the TNFAIP3 Genomic Locus With Immune-mediated TTP","A20iTTP","Patients:\n\nInclusion Criteria:\n\n* Diagnosis of iTTP\n* Above 12 years of age\n* Caucasian, Italian origin\n* Written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Patients who do not meet the above-listed criteria will be excluded from participation in the study.\n\nControls will be healthy Italian volunteers of Caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.",true,"ALL","12 Years",{"count":92,"type":93},400,"ESTIMATED","INTERVENTIONAL",[96],"NA","This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.",[99],"Thrombotic Thrombocytopenic Purpura, Acquired",[101,102,103],"A20","iTTP","TNFAIP3","2026-03-26",{"date":106,"type":107},"2026-03-27","ACTUAL",{"date":109,"type":107},"2025-04-07",{"date":111,"type":93},"2026-04",{"name":5,"class":6},1]